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Abstract
Background Mitochondrial dysfunction is a potential therapeutic target to improve skeletal muscle function, but the
contribution of mitochondrial dysfunction to impaired skeletal muscle performance in older people remains unclear.
The aim of this analysis was to test the association between measures of skeletal muscle mitochondrial function and
physical performance in older people.
Methods We analysed data from the Allopurinol in Functional Impairment trial. Participants aged 65 and over, who
were unable to walk 400 m in 6 min, underwent 31P magnetic resonance spectroscopy of the calf after exercise at base-
line and at 20 weeks follow up. The phosphocreatine recovery half-life time (t1/2) was derived as a measure of mito-
chondrial function. Participants undertook the 6-min walk test and the Short Physical Performance Battery. Muscle
mass measured using the Akern 101 bio-impedance analysis system. Bivariate correlations and multivariable regression
analyses were conducted to determine associations between t1/2 and baseline factors.
Results One hundred and seventeen participants underwent baseline 31P magnetic resonance spectroscopy, mean age
80.4 years (SD 6.0); 56 (48%) were female. Mean 6-min walk was 291 m (SD 80), mean SPPB score was 8.4 (SD 1.9);
t1/2 correlated significantly with Short Physical Performance Battery score (r= 0.22, P= 0.02) but not with 6-min walk
distance (r = 0.10, P = 0.29). In multivariable linear regression, muscle mass and total body weight, but not t1/2, were
independently associated with Short Physical Performance Battery score and with 6-min walk distance. Change in t1/2
was not significantly associated with change in Short Physical Performance Battery score (r = 0.03, P = 0.79) or with
change in 6-min walk distance (r = 0.11, P = 0.28).
Conclusions Muscle mass, but not phosphocreatine recovery time, was consistently associated with Short Physical
Performance Battery score and 6-min walk distance in older people with functional impairment.
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Background
Impaired physical performance is a common and important
finding in older people. Performance impairments may reflect
physiological derangements in a host of organ systems,
including cardiac and respiratory systems, central and periph-
eral nervous system, bones and joints, but skeletal muscle
dysfunction is an important overarching finding and major
contributor to impaired physical performance.1 Skeletal
muscle dysfunction may manifest as reduced muscle strength
and/or mass (sarcopenia), or impaired endurance. These im-
pairments contribute to the frailty syndrome2 and to a series
of adverse consequences including limitation of activities of
daily living, an increased need for care, increased risk of hos-
pital admission and falls, increased length of stay in hospital,
lower quality of life, and earlier death.3–6
Understanding the pathophysiology of impaired skeletal
muscle function in older people is essential to find better
ways to improve muscle function and hence improve physical
performance. Many different pathophysiological pathways
have been implicated, including mitochondrial dysfunction,
oxidative stress, chronic inflammation, neuromuscular junc-
tion loss, derangements of neurohormonal systems, anabolic
resistance, satellite cell loss, and cellular senescence. Work
continues at pace to dissect out the relative contribution of
these derangements, and the extent to which they contribute
to deficits in muscle size, strength, and endurance.7,8
Mitochondrial dysfunction has been suggested to be an
important component of skeletal muscle dysfunction with ad-
vancing age. Genetically inherited mitochondrial mutations
are well known to cause mitochondrial myopathies.9 Studies
of mitochondrial function measured using 31P magnetic res-
onance spectroscopy (31P MRS) show that phosphocreatine
recovery rate (a measure of how quickly mitochondria can
generate ATP to replenish phosphocreatine after exercise) is
much slower in older people with the frailty syndrome com-
pared with healthy older people.10 In contrast, phosphocrea-
tine recovery rate does not appear to be significantly slower
in healthy older people compared with younger people.11,12
It is not clear at present whether mitochondrial dysfunc-
tion is a major driver of impaired physical performance in
older people. We therefore aimed to assess the relationship
between PCr recovery rate and measures of physical perfor-
mance in a population of older people with impaired physical
function recruited to a randomized controlled trial.
Methods
Study population
The analyses described in this paper used data from the
ALFIE (Allopurinol for Functional Impairment) trial.13 The
trial enrolled 124 people aged 65 and over with impaired
physical performance (6-min walk distance <400 m) and
randomized them to receive 600 mg allopurinol or
matching placebo for 20 weeks. Exclusion criteria have
been described in full elsewhere but included contraindica-
tions to allopurinol or to MRI scanning, and diseases likely
to alter skeletal muscle function by alternative mechanisms
to those seen in the sarcopenia of ageing (including chronic
heart failure, severe COPD, peripheral arterial disease,
steroid-induced myopathy, or active malignancy). Ethics
approval was given by the East of Scotland Research Ethics
committee (approval number 14/ES/1092), and written in-
formed consent was obtained from all participants. The
study was performed in line with the principles of the
Declaration of Helsinki. The trial was approved by the UK
Medicines and Healthcare products Regulatory Authority
(CTA 2014-004122-18) and was registered at www.isrctn.
com (ISRCTN03331094).
31P magnetic resonance spectroscopy
31P magnetic resonance spectroscopy (MRS) of the calf was
performed before and after participants exercised by
repeated plantarflexion of the foot of their non-dominant
leg. Plantarflexion was performed against resistance using
an MRI-safe, weight-adjusted system. The weight was set
to provide resistance based on 15% of lean body mass14 de-
rived from bioimpedance analysis (BIA). Both sets of tests
were conducted at baseline and at 20 weeks after the inter-
vention. The full 31P MRS acquisition and analysis details
have been published previously.13 In brief, participants were
scanned using a 3T Siemens MRI scanner (Trio/PrismaFit,
Siemens Healthineers, Erlangen, Germany). A dual-tuned
1H/31P coil was used to acquire spectra every 4.2 s before
exercise and during recovery starting immediately after
cessation of plantarflexion exercise. Spectroscopy data were
processed using JMRUI15 to obtain a series of 31P MRS
measures including phosphocreatine recovery rate, ATP,
inorganic phosphate and total phosphocreatine levels pre-
and post-exercise as previously described.13,16 The maximal
rate of PCr recovery was calculated from the maximum
slope of the fitted graph for each recovery curve, with
results presented both un-normalized and normalized for
PCr depletion. The PCr recovery half time was calculated
by multiplying the time constant by ln(2); the time constant
was taken as the reciprocal of the rate constant derived
from the PCr recovery curve. The percentage PCr depletion
with exercise was calculated (previous studies have
suggested that depletion should be between 30% and 70%
to ensure sufficient depletion without generating an
acidotic environment). Resting pH and the Pi:PCr were also
calculated.
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Measures of physical performance andmuscle mass
The Short Physical Performance Battery (SPPB) was per-
formed as previously described.4 The gait speed component
was assessed over a 2.44 m walking course. The SPPB
assesses lower limb strength and balance and is a powerful
predictor of adverse outcomes including future disability,
death, and need for care.4
The 6-min walk test was conducted in a flat corridor on a
25 m course.17 Standardized encouragement was given, and
the distance walked was recorded to the nearest meter. A sin-
gle test was conducted at each timepoint. The 6-min walk
test is a submaximal test of exercise capacity and reflects
endurance as well as muscle strength; in older people, it
correlates significantly with measures of maximal exercise
tolerance including VO2max.
18–20
Bioimpedance analysis was used to derive lean body mass
using the BIA 101 analysis system (Akern Biosciences,
Pontassive, Italy). Measurements were taken in the supine
position. Appendicular lean body mass was derived using
the Sergi equation21 and adjusted for height squared to de-
rive the appendicular skeletal muscle mass index (ASMMI);
this equation was derived in a similar population of older
Europeans, using the same BIA 101 analysis system as used
in the current study.
Other covariates
In addition, a range of covariates measured during the trial
were selected for inclusion in the analyses. Blood pressure
was measured in the supine position after 5 min of rest using
an OMRON HEP-705 oscillometric device; three readings
were recorded and the mean of the second and third read-
ings were taken as the measurement for analysis. Endothelial
function was assessed by measuring flow-mediated dilation
(FMD) of the Brachial artery in response to 5 min of forearm
blood flow occlusion.22 Brachial artery diameter was mea-
sured as previously described by using a Sequoia 512 ultra-
sound machine (Siemens, Camberley, UK) and an 8-MHz
linear array ultrasound probe. 8-Hydroxydeoxyguanosine
(8-OHDG), a circulating marker of muscle oxidative stress,
was measured by an ELISA (Cusabio, Houston, TX, USA). Se-
rum urate (Sigma-Aldrich/Merck, Darmstadt, Germany) and
plasma marker of oxidative stress denoted by Thiobarbiturate
Reactive Substances (TBARS) (Cayman Chemicals, Michigan
USA) were measured by colorimetric assays.
Statistical analyses
Statistical analyses were performed using SPSS v25 (IBM,
New York, USA); a two-sided P value of <0.05 was taken as
significant for all analyses. The analysis dataset comprised
all participants who underwent 31P MRS at baseline; descrip-
tive baseline statistics were produced for this cohort. For
analysis of baseline cross-sectional data, bivariate correla-
tions between baseline physical performance measures and
baseline 31P MRS measures and other covariates were gener-
ated. Continuous variables were compared using Spearman’s
rank correlation coefficient as MRS measures were not nor-
mally distributed. Categorical variables were compared using
Student’s t-test. Multivariable analysis was then performed
using linear regression models with SPPB and 6-min walk
distance as dependent variables to explore whether 31P
MRS measures were independently associated physical
performance. Several of the MRS variables were not normally
distributed, so the log or square root of the variable was
taken to achieve a normal distribution.
Associations between the change in physical performance
between baseline and follow up and change in 31P MRS
and other covariates were similarly analysed; change scores
for each variable were calculated, then compared using
Spearman’s rank test due to the data not being normally
distributed.
Results
One hundred and seventeen participants had MRS data
collected at baseline and formed the study population, base-
line details are given in Table 1. The mean age of participants
was 80.4 years (SD 6.0); 56 (48%) were female. All partici-
pants had significantly impaired physical performance; the
mean 6-min walk was 291 m with a range of 84 to 398 m,
and the mean SPPB score was 8.4, with a range of 3 to 12.
The mean resting skeletal muscle pH was 7.23 (SD 0.09),
and the mean percentage PCr depletion with exercise was
61% (SD 18).
Baseline cross-sectional correlations
The relationship between the measures of physical perfor-
mance and phosphocreatine recovery half time (t1/2) are
show in Figure 1, along with the relationship between age
and t1/2. A significant association was seen between t1/2
and the SPPB score (rho = 0.22, P = 0.02) but not between
t1/2 and the 6-min walk distance (rho = 0.10, P = 0.29). The
mean t1/2 for the study population was 35 (SD 22) seconds
(median 31 s; interquartile range 22 to 41 s).
Table 2 shows the association between all baseline vari-
ables and the two measures of physical performance. Several
measures of phosphorus metabolism were associated with
SPPB, but only un-normalized PCr recovery rate was associ-
ated with 6-min walk distance; no significant association
was seen after normalization for PCr depletion. None of the
studied co-morbidities showed a significant association with
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either SPPB or the 6-min walk distance. Body mass index
showed a significant negative association with both SPPB
and walk distance as expected; in contrast, lean body mass
showed a positive association with both SPPB and walk
distance.
Baseline multivariable analyses
Table 3 shows the results of multivariable analyses, relating
each measure of physical performance to measures of phos-
phorus metabolism together with body weight, muscle mass
and (for the 6-min walk) height. Muscle mass and body
weight were significantly associated with both 6-min walk
distance and SPPB, but none of the MRS measures was inde-
pendently associated with 6-min walk distance or the SPPB
score.
Associations with change in physical performance
over time
Changes in normalized PCr recovery between baseline and
20 weeks showed a weak but significant correlation with
changes 6-min walk distance, but changes in other MRS
measures, urate, or measures of oxidative stress did not
correlate with changes in SPPB or 6-min walk distance.
Results are shown in Table 4.
Discussion
In this study, we found that mitochondrial function measured
by phosphocreatine recovery half time was not indepen-
dently associated with physical performance in this group
older people with functional impairment. Multivariable
analysis found that body weight and muscle mass were more
closely associated with physical performance than MRS
measures of muscle function. We also found that PCr recov-
ery time in this population was similar to that found in
healthy older populations and younger people. The lack of
correlation between most measures of change in PCr recov-
ery rate and change in physical performance over time sug-
gests that interventions to improve mitochondrial function
as measured by PCr recovery rate are unlikely to deliver im-
provements in physical function in this group of older people.
Previous studies on healthy older people have found PCr
recovery half times similar to that found in the current study.
Mean t1/2 was 36 s in a group of 16 active older people with a
mean age of 85 years11 and was 32 s in a group of six healthy
older people with ages ranging from 70 to 83 years.12 A study
of healthy older people aged 65 and over measured a mean
t1/2 of 30 s when examining quadriceps function.
23 We found
an association between older age and longer PCr recovery
rate, similar to that found in previous studies.12,23 Our results
are consistent with those from Santanasto et al.24 who found
a relationship between walk speed and PCr recovery rate in
high-functioning older people but found no such relationship
in people with functional impairment despite similar mean
PCr recovery rates between the two groups. Of note, the
mean SPPB in our study (8.4) was very similar to that seen
in the functionally impaired group studied by Santanasto
et al. (7.8). Other studies23,25 have also found significant
relationships between PCr recovery rate and walk speed over
longer distances or at faster pace, although again these
studies enrolled healthy older people.
Some of the differences seen in PCr recovery rate with age
may be due to the level of physical activity; older people who
were sedentary had much longer PCr recovery half-times
(50 s) than those who were physically active (25 s)26; older
people who were physically active showed similar PCr
recovery half-times to young active individuals. Interestingly,
in this study, measures of mitochondrial function were not
significantly associated with gait speed, chair stand time, or
stair climb time on univariate analysis but were significantly
associated with 1-repetition maximum strength and stair
climb tests when adjusted for muscle mass, age, and sex. A
similar relationship was seen between PCr recovery time
Table 1 Baseline descriptors (n = 117)
Mean age (years) (SD) 80.4 (6.0)
Female sex (%) 56 (48)
Ischaemic heart disease (%) 19 (16)
Hypertension (%) 69 (59)
Dyslipidaemia (%) 62 (53)
Stroke or transient ischaemic attack (%) 12 (10)
Diabetes mellitus (%) 18 (15)
Median weekly alcohol intake (units) (IQR) 2 (0–5)
Current smoker (%) 8 (7)
Systolic blood pressure (mmHg) (SD) 143 (18)
Diastolic blood pressure (mmHg) (SD) 77 (9)
Body mass index (kg/m2) (SD) 28.3 (4.8)
Six-min walk distance (m) (SD) 291 (80)
Lean body mass (kg) (SD)
Men 33.6 (7.6)
Women 24.5 (4.0)
Appendicular skeletal muscle mass index (kg/m2) (SD)
Men 11.3 (2.4)
Women 10.0 (1.7)
Mean short physical performance battery (SD) 8.4 (1.9)
Median total number of medications (IQR) 5 (3–8)
ACE inhibitor (%) 29 (25)
Beta-blocker (%) 20 (17)
Calcium channel blocker (%) 36 (31)
Alpha blocker (%) 12 (10)
Thiazide (%) 28 (24)
Loop diuretic (%) 10 (9)
Aldosterone antagonist (%) 4 (3)
Angiotensin receptor blocker (%) 11 (9)
Statin (%) 49 (42)
Antiplatelet (%) 28 (24)
Insulin (%) 1 (1)
Antidiabetic (%) 11 (9)
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and physical activity in healthy people enrolled in the Balti-
more Longitudinal Study of Ageing.27 These differences in
physical activity may also underlie the differences in PCr re-
covery rate seen between older women who were non-frail,
pre-frail, and frail28; similar results were seen in another
small study comparing older people living with prefrailty with
those who were not frail.29 Frailty was classified by the Fried
frailty criteria in these studies, and low levels of physical
Figure 1 Relationship between baseline phosphocreatine recovery half-time, age, and physical performance measures.
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activity are an important component of the ‘spiral of decline’
posited by the Fried frailty model.30
Another explanation may be that in older people with
functional impairment, factors other than mitochondrial
function are more important in determining physical
performance. Co-morbid disease, particularly arthritis, heart
and lung disease, but also neuromuscular disease, such as
previous stroke, chronic pain syndrome, and parkinsonian
Table 2 Associations between baseline covariates and baseline measures of physical performance continuous
Continuous covariates
6-min walk distance SPPB
r P r P
Age 0.13 0.18 0.12 0.20
PCr measures
t1/2 0.10 0.29 0.22 0.02
Normalized PCr recovery rate 0.01 0.94 0.00 0.97
Non-normalized PCr recovery rate 0.22 0.02 0.26 0.005
Resting pH 0.10 0.29 0.09 0.32
Pi:PCr ratio 0.07 0.46 0.03 0.78
%PCr depletion 0.15 0.10 0.18 0.054
Uric acid 0.10 0.28 0.05 0.61
8OHDG 0.27 0.004 0.24 0.01
TBARS 0.06 0.54 0.05 0.60
Flow-mediated brachial artery dilatation 0.22 0.06 0.23 0.05
Weight 0.13 0.17 0.12 0.22
Height 0.19 0.04 0.22 0.02
Body mass index 0.29 0.002 0.31 0.001
Lean body mass 0.23 0.01 0.26 0.005
Categorical covariates Mean (SD) P Mean (SD) P
Sex
Male 298 (83) 0.32 8.8 (1.6) 0.03
Female 283 (77) 8.0 (2.1)
Ischaemic heart disease
Yes 288 (79) 0.85 8.5 (1.6) 0.88
No 291 (81) 8.4 (2.0)
Hypertension
Yes 270 (82) <0.001 8.1 (1.9) 0.04
No 321 (68) 8.9 (1.8)
Dyslipidaemia
Yes 278 (76) 0.06 8.3 (1.9) 0.48
No 306 (83) 8.5 (2.0)
Stroke/transient ischaemic attack
Yes 284 (52) 0.75 8.6 (1.7) 0.74
No 292 (83) 8.4 (2.0)
Diabetes mellitus
Yes 244 (83) 0.006 7.7 (2.0) 0.07
No 299 (77) 8.5 (1.9)
Current smoker
Yes 309 (98) 0.51 8.3 (2.3) 0.81
No 289 (79) 8.4 (1.9)
PCr, phosphocreatine. Pi, inorganic phosphate. TBARS, thiobarbiturate reactive substances. 8OHDG, 8-hydroxydeoxyguanosine.
Table 3 Multivariable analyses
Log t1/2 Square root of non-normalized initial PCr recovery rate
B (95% CI) P B (95% CI) P
SPPB
Muscle mass 0.117 (0.060 to 0.175) <0.001 0.107 (0.050 to 0.164) <0.001
Weight 0.051 (0.081 to 0.021) 0.001 0.045 (0.075 to 0.016) 0.003
MRS measure 1.21 (0.143 to 2.55) 0.08 0.004 (0.001 to 0.009) 0.09
6 min walk distance
Muscle mass 4.29 (1.69 to 6.89) 0.001 3.58 (1.01 to 6.16) 0.007
Weight 2.87 (4.12 to 1.60) <0.001 2.35 (3.63 to 1.08) <0.001
Height 139.35 (26.8 to 305.5) 0.10 122.72 (50.26 to 295.69) 0.16
MRS measure 37.40 (146.5 to 347.66) 0.18 0.100 (0.094 to 0.298) 0.30
MRS, magnetic resonance spectroscopy; SPPB, short physical performance battery.
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syndromes, may all impair physical performance in complex
ways without mitochondrial function being the limiting
factor. Skeletal muscle perfusion has been suggested as a
limiting factor for skeletal muscle function in some older
people31 although our results did not show an association
between better endothelial function at the brachial artery
and better physical performance.
Strengths of our study were that we were able to study
MRS measures in a comparatively large group of older
people, with a mean age of over 80 years old and that we
were able to compare MRS measures with a measure of
lower limb function reflecting strength (the SPPB) as well as
a measure of endurance (the 6-min walk) reflecting comple-
mentary aspects of skeletal muscle function. Unlike most
other large studies using MRS in older people, we focused
on a group of older people with impaired physical function
—a group at risk of activity impairment and further deteriora-
tion, and thus highly relevant to clinical practice.
There are a number of limitations to our study; despite
enrolling older people with functional impairment, only two
participants fulfilled the criteria for low muscle mass
according to the revised EWGSOP criteria for sarcopenia. In
addition, we did not measure handgrip strength in this study,
which would have given additional useful information on
muscle function. Participants in any randomized controlled
trial tend to be highly selected and somewhat healthier than
the population from which they are drawn, although our
study population had significant multimorbidity. Phosphocre-
atine recovery rate is only one way of interrogating
mitochondrial function. It has the advantage of not requiring
muscle biopsy and provides a window into real-time physio-
logical response of muscle to an exercise challenge. It is
possible that other aspects of mitochondrial function are
more important in determining muscle function in older
people, but we did not undertake muscle biopsy to enable
exploration of other measures of mitochondrial structure,
density, or function.11,29 Alternatively, other factors, such as
mitochondrial number or delivery of substrates to mitochon-
dria, may provide the underlying cause for impaired skeletal
muscle function.31,32
It is unclear how well correlated MRS measures are
between different muscle groups in older people with func-
tional impairment. We studied calf muscle MRS measures,
but quadriceps measures would have been arguably more
relevant to performance in both the SPPB and 6-min walk.
Such measures are more difficult to acquire and exercising
the quadriceps to exhaustion within the MRI scanner is tech-
nically more challenging, requiring heavier weights and larger
equipment although previous studies in healthy older people
have accomplished this.27 Similarly, we derived an estimate
of appendicular muscle mass from whole-body bioimpedance
rather than measuring leg muscle mass directly using DXA or
MRI, which may have weakened correlations between
mass and MRS measures. We were unable to include
physical activity as a covariate in our analyses as this was
not measured in the trial.
We suggest that future observational studies in this
area should focus on patients with a confirmed diagnosis of
sarcopenia or physical frailty; such patients are those most
likely to manifest derangements of normal skeletal muscle
physiology. Future studies should incorporate measures of
physical activity given the important modifying influence that
inactivity appears to have on mitochondrial function. The
addition of muscle biopsy alongside MRS measures would
further augment the ability of future studies to both delin-
eate the mitochondrial pathology underlying sarcopenia and
frailty but would also help to identify which MRS measure
most closely correlated with biopsy-based measures of mito-
chondrial function. Including MRS assessment of quadriceps
function would provide data on a muscle group crucial to
daily activity in older people (such as climbing stairs and
rising from a chair).
Our results do not support strategies to improve mito-
chondrial function as the main target for improving skeletal
Table 4 Associations between changes in covariates and changes in measures of physical performance between baseline and 20 weeks
6-min walk distance change SPPB change
r P r P
MRS measures
t1/2 0.11 0.28 0.03 0.80
Normalized PCr recovery rate 0.20 0.04 0.13 0.17
Non-normalized PCr recovery rate 0.18 0.06 0.16 0.10
Resting pH 0.02 0.82 0.04 0.67
Pi:PCr ratio 0.18 0.06 0.12 0.23
%PCr depletion 0.14 0.14 0.15 0.13
Uric acid 0.10 0.30 0.08 0.43
8OHDG 0.13 0.20 0.10 0.34
TBARS 0.003 0.98 0.02 0.88
Flow-mediated dilatation of
brachial artery
0.01 0.91 0.18 0.13
Muscle mass 0.03 0.80 0.00 0.98
PCr, phosphocreatine; Pi, inorganic phosphate; TBARS, thiobarbiturate reactive substances; 8OHDG, 8-hydroxydeoxyguanosine.
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muscle function in this group of older people. However, such
a strategy may still be worth exploring in older people with
worse muscle function—that is, those who are physically in-
active, those with sarcopenia or those with more advanced
physical frailty. Future studies should therefore target these
groups for proof-of-concept studies aimed at improving mito-
chondrial function. For older people with impaired function
but without sarcopenia or frailty, alternative strategies (e.g.
nutrition, senolytics, myostatin system inhibitors, or improv-
ing skeletal muscle perfusion)1,31,32 should be explored
further to both improve muscle mass and improve skeletal
muscle function.
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